Recombinant Human Cytochrome P450 4V2 (CYP4V2)

What is CYP4V2 and what are its primary functions?

CYP4V2 is a cytochrome P450 enzyme that functions as a fatty acid omega hydroxylase with crucial roles in lipid metabolism pathways. Research has demonstrated its involvement in metabolic syndrome and non-alcoholic fatty liver disease progression through analysis of human tissue samples and mouse models . CYP4V2 appears to regulate cholesterol metabolism, which may influence cell degradative and recycling pathways . Additionally, CYP4V2 mutant cells show elevated triglycerides, free cholesterol, decreased metabolism of pro-inflammatory polyunsaturated fatty acids (PUFAs), and lack certain fatty acid-binding proteins (FABPs) . This suggests CYP4V2 serves a regulatory role in both immune system function and inflammatory responses.

What enzymatic activities have been confirmed for CYP4V2?

CYP4V2 demonstrates activity toward multiple substrates, with particularly well-characterized activity in lauric acid oxidation. Functional studies with wild-type CYP4V2 and variant proteins have established lauric acid as a key substrate for measuring enzyme function . Beyond this, proluciferin substrate assays have identified eight compounds metabolized by CYP4V2, with luciferin-BE and luciferin-3FEME being the most efficient substrates . Interestingly, luciferin-4F2/3 and luciferin-Multi Cyp, which can be converted by other human CYP4 enzymes, are not CYP4V2 substrates . These substrate specificity patterns provide valuable insights into the unique structural features of CYP4V2's active site.

What are the known genetic variants of CYP4V2 and their functional implications?

Research has identified 26 CYP4V2 genetic variants, including 7 novel variants in healthy subjects . Six protein-coding variants have been extensively studied: three novel variants (L22V, R287T, and G410C) and three previously reported variants (R36S, Q259K, and H331P) . Functional characterization revealed that CYP4V2 H331P and G410C exhibit significantly decreased activity for lauric acid oxidation (20-30% of wild-type activity), which correlates with low expression of these substituted proteins . The other four variants showed activity comparable to wild-type CYP4V2. In silico analysis predicted that H331P and G410C substitutions cause structural changes that likely explain their reduced function . Additionally, a novel compound heterozygous variant (c.C958T/p.R320X and c.G1355A/p.R452H) has been identified in a Chinese family with autosomal recessive retinitis pigmentosa .

What expression systems are effective for producing recombinant CYP4V2?

Multiple expression systems have proven effective for producing functional recombinant CYP4V2. For eukaryotic expression, 293T cells can be successfully transfected with expression vectors such as pcDNA/PDEST40 containing CYP4V2 cDNA sequences . This approach has been validated for both wild-type CYP4V2 and amino acid variants, making it suitable for functional characterization studies. Alternatively, recombinant fission yeast strains, such as RAJ232, have been developed to coexpress human CYP4V2 and cytochrome P450 reductase (CPR) . This system enables the creation of permeabilized cells (enzyme bags) that retain enzymatic activity and can be used directly in substrate metabolism assays . The choice between these systems depends on the specific research application, with mammalian cells often preferred for structural studies and yeast systems for high-throughput enzymatic assays.

How can CYP4V2 enzyme activity be measured and quantified?

Several methodologies have been established for measuring CYP4V2 activity. The most widely used approach involves assessing lauric acid oxidation, which has been effectively employed to characterize wild-type and variant CYP4V2 proteins . For high-throughput applications, luminogenic assays using proluciferin substrates provide sensitive and convenient readouts. Eight proluciferin compounds have been identified as CYP4V2 substrates, with luciferin-BE and luciferin-3FEME being the most efficient . These luminogenic substrates can be used with either purified enzyme preparations or permeabilized cells expressing recombinant CYP4V2 and CPR . Additionally, competitive enzyme immunoassay techniques utilizing anti-CYP4V2 antibodies and CYP4V2-HRP conjugates can detect native CYP4V2 in biological samples . The choice of assay depends on the specific research question, with lauric acid oxidation being the gold standard for functional characterization and proluciferin substrates preferred for inhibitor screening.

What approaches are effective for identifying and validating CYP4V2 inhibitors?

A robust testing system for identifying CYP4V2 inhibitors employs luciferin-3FEME as a probe substrate in conjunction with recombinant CYP4V2 expression systems . This approach has successfully identified several inhibitors, with HET0016 showing the strongest effect (IC50 = 179 nM) . Osilodrostat has also demonstrated statistically significant inhibitory potency . For computational approaches, homology modeling of CYP4V2 combined with docking experiments can predict binding interactions and guide inhibitor design . Importantly, inhibitor selectivity should be evaluated, as compounds that inhibit related enzymes (such as CYP4Z1) may not necessarily inhibit CYP4V2, highlighting structural differences between these cytochrome P450 enzymes . Counter-screening against related CYP enzymes is therefore essential for developing truly selective CYP4V2 inhibitors.

How are CYP4V2 mutations linked to retinal diseases?

CYP4V2 mutations have been primarily associated with Bietti crystalline dystrophy (BCD), an autosomal recessive chorioretinal degenerative disease characterized by crystalline retinal deposits, progressive retinal pigment epithelium atrophy, and choroidal sclerosis . Recent research has expanded this disease spectrum, with evidence that certain CYP4V2 variants can also cause retinitis pigmentosa (RP) . Whole-exome sequencing identified a novel compound heterozygous variant (c.C958T/p.R320X and c.G1355A/p.R452H) in the CYP4V2 gene in a non-consanguineous Chinese family with autosomal recessive RP . This variant was absent in unaffected family members and 400 ethnically-matched healthy control individuals, strongly suggesting it as disease-causing . The mechanism linking CYP4V2 dysfunction to retinal degeneration likely involves disrupted lipid metabolism, as CYP4V2 mutant cells exhibit elevated triglycerides and free cholesterol .

What is the emerging role of CYP4V2 in metabolic disorders?

CYP4V2 has been implicated in metabolic syndrome and non-alcoholic fatty liver disease progression through analysis of human metabolic associated fatty liver disease (MAFLD) tissue samples and mouse models representing the MAFLD spectrum (normal liver, steatosis, non-alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma) . Mechanistically, CYP4V2 appears to influence cholesterol metabolism, which may regulate cell degradative and recycling pathways . This connection is supported by evidence that cholesterol reduction via cyclodextrins and delta-tocopherol treatment ameliorates Bietti crystalline dystrophy phenotypes . Additionally, CYP4V2 mutant cells lack two fatty acid-binding proteins responsible for trafficking fatty acids throughout cellular organelles and the nucleus, further expanding CYP4V2's potential role in fatty acid metabolic pathways . The enzyme's involvement in metabolism of pro-inflammatory polyunsaturated fatty acids also suggests it may regulate inflammatory responses central to metabolic disease pathogenesis .

How can genetic variants of CYP4V2 be classified for clinical significance?

Classification of CYP4V2 genetic variants requires integration of multiple lines of evidence. Whole-exome sequencing (WES) provides a comprehensive approach for initial variant identification, as demonstrated in studies of families with autosomal recessive retinitis pigmentosa . After WES analysis, variants should be filtered through population databases (dbSNP138, 1000 Genomes Project, Exome Aggregation Consortium) to eliminate common variants unlikely to be pathogenic . Functional variants including frameshift indels, non-synonymous variants, and splicing junction variants should be prioritized . Validation through Sanger sequencing and co-segregation analysis in affected families is essential . Bioinformatics tools such as Mutation Taster, CADD, PROVEAN, PolyPhen-2, Panther, and SIFT can predict the potential pathogenic effects of amino acid substitutions . Finally, functional characterization through enzyme activity assays (e.g., measuring lauric acid oxidation) provides direct evidence of variant impact on protein function .

How can structure-function relationships of CYP4V2 be investigated?

Structure-function relationships of CYP4V2 can be investigated through complementary computational and experimental approaches. Homology modeling based on related cytochrome P450 structures provides insights into the three-dimensional organization of CYP4V2 . These models can be used for docking studies with substrates and inhibitors to predict key binding interactions . Experimentally, site-directed mutagenesis of specific residues followed by functional assays with substrates like lauric acid or luciferin derivatives can validate computational predictions . Comparison of wild-type and variant proteins (such as H331P and G410C) that show reduced activity offers valuable insights into critical structural regions . The correlation between reduced protein expression and decreased enzymatic activity for certain variants suggests that structural integrity affects both protein stability and function . Integration of structural modeling with experimental data provides the most comprehensive understanding of CYP4V2 structure-function relationships.

What are the most promising therapeutic strategies targeting CYP4V2?

Based on current understanding of CYP4V2 biology, several therapeutic strategies show promise. For conditions involving enhanced CYP4V2 activity, selective inhibitors like HET0016 (IC50 = 179 nM) could modulate enzyme function . Conversely, for diseases caused by loss-of-function mutations, gene therapy approaches similar to those developed for other retinal diseases might restore functional CYP4V2 expression. Alternatively, targeting downstream metabolic pathways affected by CYP4V2 dysfunction shows potential, as demonstrated by the amelioration of Bietti crystalline dystrophy phenotypes through cholesterol reduction via cyclodextrins and delta-tocopherol treatment . For metabolic disorders linked to CYP4V2, modulating fatty acid metabolism or inflammatory pathways influenced by CYP4V2 could provide therapeutic benefit . The choice of strategy depends on whether the pathology results from gain or loss of function and the specific tissue affected.

What challenges exist in developing specific and sensitive assays for CYP4V2 in complex biological samples?

Developing specific and sensitive assays for CYP4V2 in complex biological samples presents several challenges. The ELISA kit approach utilizes a competitive enzyme immunoassay technique with anti-CYP4V2 antibodies and CYP4V2-HRP conjugates, where the intensity of color is inversely proportional to the CYP4V2 concentration . This method is suitable for undiluted body fluids and tissue homogenates but may face cross-reactivity issues with related cytochrome P450 enzymes . Activity-based assays using specific substrates like luciferin-3FEME provide functional readouts but require careful optimization for complex samples . The potential presence of multiple CYP4V2 variants with different activities in human populations complicates interpretation . Additionally, low expression levels in certain tissues may necessitate highly sensitive detection methods. Future assay development should focus on increased specificity through antibodies targeting unique CYP4V2 epitopes or highly selective substrates that distinguish CYP4V2 from related enzymes.

How should researchers interpret substrate specificity data for CYP4V2?

Interpretation of CYP4V2 substrate specificity data requires careful consideration of several factors. The observation that eight of ten tested proluciferin compounds are metabolized by CYP4V2, with luciferin-BE and luciferin-3FEME being the most efficient substrates, provides valuable insights into the enzyme's active site preferences . Interestingly, luciferin-4F2/3 and luciferin-Multi Cyp, which are substrates for other human CYP4 enzymes, are not metabolized by CYP4V2 . This distinct substrate specificity profile suggests structural differences between CYP4V2 and related enzymes. When comparing substrate preferences across studies, researchers should consider differences in expression systems, assay conditions, and the presence of necessary cofactors like cytochrome P450 reductase. The lauric acid oxidation assay remains valuable for functional characterization of variants , while proluciferin substrates may be more suitable for high-throughput applications like inhibitor screening .

How can researchers integrate metabolomic and genomic data to understand CYP4V2 function?

Integration of metabolomic and genomic data provides powerful insights into CYP4V2 function. Studies of CYP4V2 mutant cells have revealed elevated triglycerides and free cholesterol, suggesting specific metabolic pathways affected by enzyme dysfunction . These findings can be correlated with genetic data from patients with conditions like Bietti crystalline dystrophy or retinitis pigmentosa to establish genotype-phenotype relationships . The observation that CYP4V2 mutant cells lack two fatty acid-binding proteins highlights potential downstream effects that can be further explored through targeted metabolomics . When metabolomic abnormalities are identified, genetic rescue experiments introducing wild-type or variant CYP4V2 can confirm causal relationships. Additionally, comparing metabolic profiles across different tissues in models with CYP4V2 mutations can reveal tissue-specific functions. This integrated approach has successfully linked CYP4V2 to both retinal diseases and metabolic disorders like non-alcoholic fatty liver disease , demonstrating the value of combining genomic and metabolomic methodologies.

What are the key unanswered questions about CYP4V2 biology?

Despite significant progress, several key questions about CYP4V2 biology remain unanswered. The complete spectrum of physiological substrates for CYP4V2 across different tissues has not been fully characterized, though some progress has been made with proluciferin compounds and lauric acid . The three-dimensional structure of CYP4V2 has been approached through homology modeling , but experimental structure determination would provide crucial insights for drug design. The precise mechanisms linking CYP4V2 dysfunction to retinal degeneration in Bietti crystalline dystrophy and retinitis pigmentosa require further elucidation . Similarly, while CYP4V2 has been implicated in metabolic-associated fatty liver disease progression , the specific metabolic pathways regulated by CYP4V2 in hepatocytes need clarification. The regulation of CYP4V2 expression in different tissues and conditions remains largely unexplored. Addressing these questions will significantly advance understanding of CYP4V2 biology and its therapeutic targeting.

How might advances in gene editing and delivery systems impact CYP4V2-focused therapeutics?

Advances in gene editing and delivery systems offer promising approaches for CYP4V2-focused therapeutics, particularly for conditions caused by loss-of-function mutations. For retinal diseases like Bietti crystalline dystrophy and retinitis pigmentosa associated with CYP4V2 mutations , adeno-associated virus (AAV) vectors could potentially deliver functional CYP4V2 to retinal pigment epithelium cells. CRISPR-Cas9 technology might enable correction of specific mutations, such as the compound heterozygous variant identified in retinitis pigmentosa patients . For metabolic disorders linked to CYP4V2 dysfunction , lipid nanoparticles could deliver mRNA encoding functional CYP4V2 to hepatocytes. The development of tissue-specific promoters would allow targeted expression in relevant cell types. Additionally, the identification of compounds that can modulate CYP4V2 activity or stabilize mutant proteins, similar to pharmacological chaperones developed for other enzymes, represents a complementary therapeutic strategy that could benefit from structural insights gained through CYP4V2 modeling .

What interdisciplinary approaches might accelerate understanding of CYP4V2 in health and disease?

Accelerating understanding of CYP4V2 requires interdisciplinary approaches combining expertise from multiple fields. Integration of structural biology techniques (X-ray crystallography, cryo-electron microscopy) with computational modeling would provide crucial insights into CYP4V2's three-dimensional structure and substrate interactions . High-throughput metabolomics coupled with genetic manipulation in cellular and animal models could identify physiological substrates and metabolic pathways regulated by CYP4V2 . Clinical collaborations focusing on detailed phenotyping of patients with CYP4V2 mutations would clarify genotype-phenotype relationships and disease mechanisms . Pharmaceutical chemistry approaches could develop selective CYP4V2 inhibitors as both research tools and potential therapeutics . Systems biology integrating transcriptomic, proteomic, and metabolomic data could reveal broader regulatory networks involving CYP4V2. Finally, translational research bridging basic science findings with clinical applications would accelerate the development of diagnostic tools and therapeutic strategies for CYP4V2-associated diseases.